The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
VITRAKVI is FDA-indicated to treat solid tumors
Bayer‘s Vitrakvi is a kinase inhibitor that is FDA indicated to treat adult and pediatric patients with solid tumors. Specifically, FDA indicates it for solid tumors with the following criteria: Presence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. Metastatic or where surgical resection is likely to result in severe morbidity.…